- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01095679
Baclofen and Hypoxia-induced Periodic Ventilation (PERIODIBAC)
Assessment of the Effect of the GABA-B Receptor Agonist, Baclofen, on Hypoxia-induced Periodic Ventilation, in Healthy Subjects
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Rationale of the study:
Periodic ventilation, often called CHEYNE Stokes ventilation, results from a dysfunction of the mechanisms of the control of breathing. In this type of ventilation, alternating periods of hyperventilation and apneas and/or hypoventilation replace the normal regular pattern of breathing. Periodic ventilation occurs preferentially during sleep. It is responsible for decreases in arterial saturation in oxygen and for sleep fragmentation. There is currently no consensual treatment but non-invasive nocturnal mechanical ventilation is often used to bring the ventilatory pattern back to normal.
Periodic ventilation occurs in various conditions, the most frequent being cardiac failure. It also occurs in healthy subjects exposed to hypoxia or at high altitude.
The pathophysiology of periodic breathing remains poorly understood. Our hypothesis regarding the mechanisms of this abnormal ventilatory pattern is based on comparative physiology. Periodic ventilation is indeed the usual ventilatory pattern of many lower vertebrates. Moreover, even isolated in VITRO, the tadpole brainstem still produces a periodic ventilatory rhythm, characterized by clusters of ventilatory discharges. In this model, the agonist of the GABA-B receptor, the baclofen, transforms the periodic pattern into a regular one. Of note, the baclofen is already used in the treatment of some human diseases, especially against spasticity.
The hypothesis of the research project assumes that periodic ventilation in humans results from a neural reconfiguration of the networks that command breathing, leading them to produce an ancestral behavior. It also assumes that the baclofen woul reverse this phenomenon as it does in the model of the tadpole isolated brainstem.
The goal of the project is therefore to assess the effect of baclofen on hypoxia-induced periodic ventilation in healthy subjects during sleep. This is thus a pathophysiological study that aimed at demonstrating a concept before a possible clinical trial.
This study is pathophysiological study, conducted in healthy volunteers only.
Methods:
The subjects will sleep in hypoxic conditions, with a level of hypoxia similar to the one that is found at an altitude of 4000-4500 meters. A this altitude, the partial pressure of oxygen is approximately 90-100 mmHg. The hypoxic atmosphere will be created in a tent with an hypoxic generator (EVEREST Summit Hypoxic Generator, Hypoxic Systems, New York, NY, USA).
The electroencephalographic and electrocardiographic signals and the movements of the chest and of the abdomen will be recorded with a portable polysomnograph. The electromyogram of the chin and the ELECTRO Oculogram will also be recorded. These signals will permit to identify the sleep stages. The subjects will ware a face mask connected to a pneumotachometer for the recording of the ventilatory flow. Gas will also be sampled to measure the end tidal partial pressure of CO2.
Protocol:
Healthy volunteers will be enrolled after they will have given written informed consent. The subjects will be asked about their medical history and physical examination will be performed. Chest X-ray, electrocardiogram and pulmonary function tests will also be performed.
The subject will be asked not to sleep the night before each recording in hypoxic conditions (the hypoxic sessions). The recordings will be performed either during a nap in the afternoon or at night.
A first hypoxic session will be performed to identify the subjects who will develop periodic ventilation. Only those who will exhibit periodic ventilation during sleep will continue the study. They will be prescribed either baclofen or placebo (double blind, randomized). The posology will be progressively increased (over approximately 10 days) to reach 20 mg 3 times a day, during 3 to 5 days. A second hypoxic session will be performed under this treatment. Then the posology will be decreased over 3 days and a complete weaning will be performed during 5 to 10 days. The same protocol will be repeated, either with baclofen or placebo (depending of the previous run) and a third hypoxic session will be performed. The posology will then be decreased over 3 days and the study will be considered ended for the subject after 2 more days of complete weaning.
The maximum duration of the study for one subject will be 63 days.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Paris, France, 75013
- Pitié-Salpêtrière Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult
- Male
- Body mass index between 20 and 30 kg/m2
- Healthy (no known disease)
- No regular treatment except first grade antalgic drugs (e. g. ACETAMINOFEN)
- Written consent to participate in the study
- Health insurance
Exclusion Criteria:
- Intolerance to baclofen
- Tobacco, alcohol or drug consumption
- Past history of possible acute mountain sickness
- Regular treatment for any disease
- Claustrophobia
- Coronary disease
- Hypertension
- Cardiac failure
- Cardiac rhythm abnormalities
- Pulmonary hypertension
- Any pulmonary artery abnormality
- Any cardiac disease
- Past history of cerebral ischemia
- Past history of psychiatric disorder
- Any respiratory disease (including asthma)
- Leg arteriopathy
- Sickle cell anemia
- Renal insufficiency
- Migraine
- Diabetes
- Obesity
- Thalassemia
- Scoliosis
- Past history of phlebitis
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Breaking tablets of 10 mg of placebo.
Dosage and frequency : 5 mg 3 times a day for 3 days, then 10 mg 3 times a day for 3 days, then 15 mg 3 times a day for 3 days, then 20 mg 3 times a day for 3-5 days, then 15 mg 3 times a day for 1 day, then 10 mg 3 times a day for one day, then 5 mg 3 times a day for one day.
|
Experimental: Baclofen
|
Breaking tablets of 10 mg of baclofen.
Dosage and frequency : 5 mg 3 times a day for 3 days, then 10 mg 3 times a day for 3 days, then 15 mg 3 times a day for 3 days, then 20 mg 3 times a day for 3-5 days, then 15 mg 3 times a day for 1 day, then 10 mg 3 times a day for one day, then 5 mg 3 times a day for one day.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Decrease in the coefficient of variation of the period of the ventilatory cycle
Time Frame: During the second and the third session in hypoxia
|
The primary outcome will be the decrease in the coefficient of variation of the period of the ventilatory cycle.
The measures will be taken during the second and the third session in hypoxia.
This means, for each subject, after having taken either placebo or 60 mg per day of Baclofen for 3-5 days.
|
During the second and the third session in hypoxia
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Decrease in the coefficient of variation of the tidal volume
Time Frame: During the second and the third session in hypoxia
|
Decrease in the coefficient of variation of the tidal volume.
The measures will be taken during the second and the third session in hypoxia.
This means, for each subject, after having taken either placebo or 60 mg per day of Baclofen for 3-5 days.
|
During the second and the third session in hypoxia
|
Decrease in the coefficient of variation of the end tidal CO2 pressure
Time Frame: During the second and the third session in hypoxia
|
Decrease in the coefficient of variation of the end tidal CO2 pressure.
The measures will be taken during the second and the third session in hypoxia.
This means, for each subject, after having taken either placebo or 60 mg per day of Baclofen for 3-5 days.
|
During the second and the third session in hypoxia
|
Decrease in the number of frequency compounds of the ventilatory flow
Time Frame: During the second and the third session in hypoxia
|
Decrease in the number of frequency compounds of the ventilatory flow.
The measures will be taken during the second and the third session in hypoxia.
This means, for each subject, after having taken either placebo or 60 mg per day of Baclofen for 3-5 days.
|
During the second and the third session in hypoxia
|
Decrease in the apnea-hypopnea index
Time Frame: During the second and the third session in hypoxia
|
Decrease in the apnea-hypopnea index.
The measures will be taken during the second and the third session in hypoxia.
This means, for each subject, after having taken either placebo or 60 mg per day of Baclofen for 3-5 days.
|
During the second and the third session in hypoxia
|
Decrease in the sleep fragmentation index
Time Frame: During the second and the third session in hypoxia
|
Decrease in the sleep fragmentation index.
The measures will be taken during the second and the third session in hypoxia.
This means, for each subject, after having taken either placebo or 60 mg per day of Baclofen for 3-5 days.
|
During the second and the third session in hypoxia
|
Change in the non-linea dynamics of the ventilatory flow
Time Frame: During the second and the third session in hypoxia
|
Change in the non-linea dynamics of the ventilatory flow.
The measures will be taken during the second and the third session in hypoxia.
This means, for each subject, after having taken either placebo or 60 mg per day of Baclofen for 3-5 days.
|
During the second and the third session in hypoxia
|
Collaborators and Investigators
Investigators
- Principal Investigator: Christian Straus, MD, PhD, Assistance Publique - Hôpitaux de Paris
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Respiration Disorders
- Signs and Symptoms, Respiratory
- Cheyne-Stokes Respiration
- Hypoxia
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- GABA Agents
- Neuromuscular Agents
- Muscle Relaxants, Central
- GABA Agonists
- GABA-B Receptor Agonists
- Baclofen
Other Study ID Numbers
- P090207
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on CHEYNE Stokes Respiration
-
University of OsloResMedCompletedHeart Failure | Cheyne Stokes RespirationNorway
-
ResMedCompletedSubstudy on the Mechanistic Plausibility of the Clinical Benefits of Adaptive Servo-ventilation (MS)Heart Failure | Sleep Disorder | Cheyne Stokes RespirationAustralia, Germany, Switzerland, Netherlands, France, Finland, Czech Republic, United Kingdom
-
Respicardia, Inc.CompletedSleep Apnea | Sleep Disordered Breathing | Periodic Breathing | Central Sleep Apnea | Cheyne Stokes RespirationUnited States, Poland, Germany, Italy
-
Umeå UniversitySwedish Heart Lung FoundationCompleted
-
ResMedCompletedCheyne-Stokes Respiration | Periodic BreathingGermany
-
Heart and Diabetes Center North-Rhine WestfaliaCompletedObstructive Sleep Apnoea | Cheyne Stokes Respiration | Central Sleep ApnoeaGermany
-
Umeå UniversityCompleted
-
ResMedCompletedCheyne-Stokes Respiration | Heart Failure, CongestiveAustralia
-
Heart and Diabetes Center North-Rhine WestfaliaTerminatedHigh-Flow-Therapy for the Treatment of Cheyne-Stokes-Respiration in Chronic Heart Failure (FLOAT-CS)Heart Failure,CongestiveGermany
-
Goethe UniversityCompletedEnvironmental Sleep Disorder | Cheyne-Stokes Respiration | Altitude SicknessGermany
Clinical Trials on Baclofen
-
Tanta UniversityUnknownLiver Cirrhosis | Muscle CrampsEgypt
-
Impax Laboratories, LLCCompletedMultiple SclerosisUnited States, Canada, Estonia, Latvia, Ukraine
-
University of MinnesotaParalyzed Veterans of America Research FoundationCompleted
-
Allaysis, LLCUniversity of MinnesotaUnknownIntravenous Baclofen
-
Amsterdam UMC, location VUmcMedtronicNot yet recruitingCerebral Palsy | Intrathecal Baclofen
-
Hospices Civils de LyonNot yet recruitingBenzodiazepine DependenceFrance
-
Tanta UniversityRecruitingMorbid Obesity | Postoperative Nausea and Vomiting | Laparoscopic Sleeve GastrectomyEgypt
-
Vanderbilt UniversityMedtronicCompleted
-
Shaare Zedek Medical CenterTerminatedCerebral PalsyIsrael
-
Imperial College LondonMedical Research CouncilCompleted